

Reflux Esophagitis (Gastroesophageal Reflux Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/R7ACEF80D150EN.html>

Date: March 2022

Pages: 117

Price: US\$ 2,000.00 (Single User License)

ID: R7ACEF80D150EN

Abstracts

Reflux Esophagitis (Gastroesophageal Reflux Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the oesophagus, that condition is called Gastroesophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Reflux

Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 9, 13, 4 and 5 respectively.

Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in
Therapeutics Development

Addpharma Inc

Ahn-Gook Pharmaceutical Co Ltd

CalyGene Biotechnology Inc

Cancer Advances Inc

Changchun Serene Pharmaceutical Co Ltd

Chong Kun Dang Pharmaceutical Corp

Cinclus Pharma AG

Daewoong Co Ltd

Eisai Co Ltd

EsoCap AG

Hana Pharm Co Ltd

Hanmi Pharmaceuticals Co Ltd

HK inno.N Corp

Ilyang Pharmaceutical Co Ltd

ISOThrive Inc

Jiangsu Carephar Pharmaceutical Co Ltd

Korea Pharma Co Ltd

Korea United Pharm Inc

Onconic Therapeutics Co Ltd

RaQualia Pharma Inc

Renexxion LLC

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Co Ltd

Trio Medicines Ltd
Xiamen Encheng Pharmaceutical Co Ltd
XuanZhu Biological Technology Co Ltd
Yooyoung Pharm Co Ltd
Yuhan Corp
Yungjin Pharm Co Ltd
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profiles
AD-206 - Drug Profile
Product Description
Mechanism Of Action
AD-212 - Drug Profile
Product Description
Mechanism Of Action
AD-213 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AD-214 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AG-1813 - Drug Profile
Product Description
Mechanism Of Action
azeloprazole sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
ceclazepide - Drug Profile
Product Description
Mechanism Of Action
CG-20043 - Drug Profile
Product Description
Mechanism Of Action
CJ-30065 - Drug Profile
Product Description
Mechanism Of Action
CJ-30076 - Drug Profile
Product Description

Mechanism Of Action
CJ-30077 - Drug Profile
Product Description
Mechanism Of Action
CJ-30078 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CKD-382 - Drug Profile
Product Description
Mechanism Of Action
History of Events
dexlansoprazole DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drug for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Drug Profile
Product Description
Mechanism Of Action
esomeprazole - Drug Profile
Product Description
Mechanism Of Action
History of Events
esomeprazole - Drug Profile
Product Description
Mechanism Of Action
History of Events
fexuprazan - Drug Profile
Product Description
Mechanism Of Action
History of Events
G-17DT - Drug Profile
Product Description
Mechanism Of Action
History of Events
ilaprazole DR - Drug Profile
Product Description
Mechanism Of Action
History of Events

INC-005 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ISOT-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

IYHCR-17 - Drug Profile

Product Description

Mechanism Of Action

History of Events

JP-1366 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KBP-3571 - Drug Profile

Product Description

Mechanism Of Action

History of Events

konolazan hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

KP-201 - Drug Profile

Product Description

Mechanism Of Action

lemborexant - Drug Profile

Product Description

Mechanism Of Action

History of Events

linaprazan glurate - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibodies to Inhibit BMP2 and BMP4 for Barretts Esophagus - Drug Profile

Product Description

Mechanism Of Action

History of Events

naronapride - Drug Profile

Product Description

Mechanism Of Action

History of Events

netazepide - Drug Profile

Product Description

Mechanism Of Action

History of Events

pantoprazole DR - Drug Profile

Product Description

Mechanism Of Action

History of Events

PTBC - Drug Profile

Product Description

Mechanism Of Action

SOCC-2 - Drug Profile

Product Description

Mechanism Of Action

tegoprazan - Drug Profile

Product Description

Mechanism Of Action

History of Events

UI-049 - Drug Profile

Product Description

Mechanism Of Action

UI-058 - Drug Profile

Product Description

Mechanism Of Action

History of Events

vonoprazan fumarate - Drug Profile

Product Description

Mechanism Of Action

History of Events

XY-066 - Drug Profile

Product Description

Mechanism Of Action

YHC-1139 - Drug Profile

Product Description

Mechanism Of Action

YPI-009 - Drug Profile

Product Description

Mechanism Of Action

YPI-011 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development

Milestones

Featured News & Press Releases

Mar 14, 2022: Phathom Pharmaceuticals submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis

Mar 07, 2022: Announcement of Luoxin Pharmaceutical on the approval of Tigola raw tablets to carry out clinical trials for new indications

Feb 21, 2022: HK inno.N predicts global success of K-Cab based on evidence

Feb 11, 2022: Regulator OKs inno. N's orally disintegrating tablet formulation for K-CAB

Feb 09, 2022: Phathom Pharmaceuticals announces positive topline results from phase 2 trial evaluating vonoprazan for non-erosive gastroesophageal reflux disease (NERD)

Oct 07, 2021: Entering China's tens of billions of acid suppression market, Shanghai Pharmaceuticals introduced blockbuster new drugs for RMB 690 million

Sep 27, 2021: Phathom Pharmaceuticals announces results from VONO-103, a phase 1 study evaluating gastric acid inhibition of Vonoprazan and Lansoprazole (PREVACID)

Sep 06, 2021: Cinclus Pharma receives approval of the International Nonproprietary Name (INN) linaprazan glurate for its lead drug candidate for the treatment of GERD

Aug 18, 2021: Cinclus Pharma announces the first patient randomized in the Phase II study for X842 in GERD

Mar 22, 2021: Application for manufacturing and marketing approval for orally disintegrating tablets of 'Takecab Tablets', a therapeutic agent for acid-related diseases

Feb 01, 2021: Gastroesophageal reflux disease new drug K-Cab, launches in China

Dec 30, 2020: Daewoong Pharmaceutical's new drug for gastroesophageal reflux disease, "Peksuprazan," approved for phase 3 in China

Dec 14, 2020: Phathom Pharmaceuticals announces plans to initiate vonoprazan development program in non-erosive reflux disease (NERD)

Nov 23, 2020: Korea's new drug, K-Cap, expands its entry into Asia

Nov 06, 2020: Daewoong Pharmaceutical announces publication of novel P-CAB fexuprazan phase 1 bridging study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Addpharma Inc, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by CalyGene Biotechnology Inc, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cancer Advances Inc, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Changchun Serene Pharmaceutical Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cinclus Pharma AG, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Daewoong Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by EsoCap AG, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Hana Pharm Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by HK inno.N Corp, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ilyang Pharmaceutical Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by ISOThrive Inc, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Korea Pharma Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Korea United Pharm Inc, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Onconic Therapeutics Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Renexxion LLC, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Trio Medicines Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Xiamen Encheng Pharmaceutical Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by XuanZhu Biological Technology Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yooyoung Pharm Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yuhan Corp, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yungjin Pharm Co Ltd, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, 2022 (Contd..1)

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, 2022 (Contd..2)

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, 2022

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Reflux Esophagitis (Gastroesophageal Reflux Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/R7ACEF80D150EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R7ACEF80D150EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

